shares of bluebird bio inc increased 14 to 674 on tuesday after a raymond james analyst raised the stock price target for the company on the heels of another approval from the food and drug administration last friday the company said the fda approved skysona for boys between the ages of 4 and 17 with early active cerebral adrenoleukodystrophy this comes a month after the agency approved bluebirds zynteglo gene therapy for patients who rely on regular blood transfusions because of a genetic disease called betathalassemia raymond james analyst dane leone said in a monday note that he sees the companys two fda approvals including one with an ongoing clinical hold as derisking events for the approval of its lovocel gene therapy for sickle cell disease also the anticipated monetization of the two priority review vouchers for elicel and beticel puts the company in a much better financial position he said raymond james raised its price target for bluebird to 10 from 8 per share shares have declined 33 for the year